According to a recent LinkedIn post from Osmind, CEO Lucia Huang recently spoke at NatCon26 on operational readiness for psychedelic medicine in psychiatric practices. The post highlights that practices integrating multiple modalities—medication management, therapy, and interventional psychiatry such as Spravato and TMS—may be better positioned for patient outcomes and retention.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post also underscores that billing for interventional psychiatry is complex, with prior authorization and benefits verification described as substantial revenue-operations functions rather than administrative afterthoughts. This emphasis suggests growing demand for specialized workflow and revenue-cycle tools, a segment in which Osmind is seeking to position its software platform.
As shared in the post, Huang’s comments further suggest that clinics interested in future psychedelic treatments need to invest early in staff training, technology, documentation, and compliance infrastructure. For investors, this framing points to a potential expansion opportunity for Osmind as clinics upgrade systems ahead of longer, higher-cost psychedelic treatment protocols.
The post implies that practices treating psychedelic medicine as a comprehensive operational build could be better prepared to capture new revenue streams as regulations and reimbursement evolve. If Osmind can align its product roadmap and services with these emerging needs, it could strengthen its competitive position in the behavioral health technology market and deepen relationships with high-value clinical customers.